Elsevier Launches Current Opinion in Virology
Helping virologists keep up-to-date in a fast-moving field
Amsterdam, 12 July 2011 – Elsevier has announced the publication of the first issue of Current Opinion in Virology - a new journal in its prestigious Current Opinion series, publishing six issues a year. Current Opinion in Virology was launched to provide a systematic, comprehensive and filtered approach to the ever-expanding wealth of research published on viruses and viral interaction: a platform to help busy specialists keep up-to-date with the latest trends and topics in virology research. The journal publishes invited review papers only and is divided into twelve annual sections, including viral genomics, antivirals and resistance, emerging viruses and virus evolution.
The editorial board is led by Editors in Chief Mary Estes (Baylor College of Medicine, USA) and Ab Osterhaus (Erasmus MC, The Netherlands). “Virology is a discipline that is dynamic, multidisciplinary and important to our lives in many ways,” states Dr. Estes. “When approached about starting a new journal in virology, we came to the conclusion that the principle and quality of the Current Opinion series in other topics made it an attractive medium to communicate new information in a broad range of virology topics. Looking beyond the successful launch of the journal,” Dr Estes concluded, “we look forward, as the virology field, technologies and world continues to change, to Current Opinion in Virology becoming one of the most highly respected journals in the field.”
All articles in the first issue are freely available online ( http://www.sciencedirect.com/science/journal/18796257 ). More information on the journal can be found on the website http://www.current-opinion.com/journals/current-opinion-in-virology.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
Phone +31 20 485 3835